RP-L102

Phase 1UNKNOWN

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Fanconi Anemia Complementation Group A

Conditions

Fanconi Anemia Complementation Group A

Trial Timeline

Jan 11, 2019 → Mar 1, 2022

NCT ID

NCT03814408

About RP-L102

RP-L102 is a phase 1 stage product being developed by Rocket Pharmaceuticals for Fanconi Anemia Complementation Group A. The current trial status is unknown. This product is registered under clinical trial identifier NCT03814408. Target conditions include Fanconi Anemia Complementation Group A.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04248439	Phase 2	Active	Jul 15, 2020	May 5, 2026	Fanconi Anemia Complementation Group A
NCT04069533	Phase 2	Active	Nov 28, 2019	Feb 1, 2025	Fanconi Anemia Complementation Group A
NCT03814408	Phase 1	UNKNOWN	Jan 11, 2019	Mar 1, 2022	Fanconi Anemia Complementation Group A

Competing Products

4 competing products in Fanconi Anemia Complementation Group A

See all competitors

Product	Company	Stage	Hype Score
Etanercept	Amgen	Phase 1	32
RP-L102	Rocket Pharmaceuticals	Phase 2	44
RP-L102	Rocket Pharmaceuticals	Phase 2	44
Busulfan + Fludarabine + Cyclophosphamide + Anti-Thymocyte Globulin (Rabbit) + G-CSF	Brain Biotech	Phase 2	44

Other Products from Rocket Pharmaceuticals